Why Multiple Queries Were Used

1. Your request was very specific

2. The medical library database requires navigation in steps

• Step 1 - Find which books exist (catalog lookup)
• Step 2 - Search headings/index to find relevant chapters
• Step 3 - Get the exact file path and line numbers
• Step 4 - Read the actual content from those locations

3. "ANCA-associated pulmonary vasculitis" spans multiple chapters

• GPA (Wegener's)
• MPA (Microscopic Polyangiitis)
• EGPA (Churg-Strauss)
• Pathophysiology
• Treatment
• DAH / Pulmonary-renal syndrome

4. Parallel queries were used to save time

ANCA-Associated Pulmonary Vasculitis

1. DEFINITION AND CLASSIFICATION

2. EPIDEMIOLOGY

• Annual incidence of all AAV combined: 6-32 per million
• GPA: incidence 4.9-10.5 per million; prevalence 24-157 per million
• MPA: incidence 2.7-11.6 per million; prevalence 0-66 per million
• EGPA: incidence 0.5-4.2 per million; prevalence 7-38 per million
• GPA is most common in Europe; MPA is more common in East Asia
• Epidemiology differs among ethnicities in both ANCA specificity and clinical manifestations

3. PATHOPHYSIOLOGY

A. Etiology

B. Genetic Factors

• Genome-wide association studies show GPA and MPA are genetically distinct
• The strongest genetic associations are based on ANCA antigen specificity (PR3 vs MPO) rather than clinical syndrome
• PR3-ANCA: strong associations with HLA-DP, SERPINA1 (codes for α1-antitrypsin - the major inhibitor of PR3), and PRTN3 gene (encodes PR3)
• MPO-ANCA: association only with HLA-DQ

C. Key Pathogenic Mechanisms

1. Priming of neutrophils by cytokines (TNF-α, IL-8) - upregulates surface expression of PR3 and MPO
2. ANCA binding to primed neutrophils → neutrophil activation
3. Neutrophil respiratory burst → release of reactive oxygen species and proteolytic enzymes
4. Endothelial damage and vessel wall destruction
5. Alternative pathway complement activation also plays a role

D. Clinical Significance of PR3 vs MPO

• Patients with PR3-ANCA have:
  • Higher relapse rate
  • More rapid loss of renal function
• Patients with MPO-ANCA have:
  • Lower relapse rate
  • Better renal outcomes
• Separating patients by ANCA specificity provides more clinically informative classification than grouping by conventional phenotypic diagnosis

4. ORGAN SYSTEM INVOLVEMENT

5. GRANULOMATOSIS WITH POLYANGIITIS (GPA)

A. Definition

B. Clinical Presentation

• Nasal congestion, epistaxis due to mucosal friability and ulceration
• Chronic sinusitis, serous otitis media
• Saddle nose deformity - from ischemia of nasal cartilage
• Gingival hyperplasia, oropharyngeal ulcerations
• Subglottic stenosis - in ~20%, can be life-threatening

• Cough, hemoptysis, dyspnea, chest pain
• Pulmonary nodules (may cavitate)
• Diffuse alveolar hemorrhage (DAH) - in <20%, reflects diffuse capillaritis

• Focal necrotizing glomerulonephritis (pauci-immune)
• Rapidly progressive crescentic glomerulonephritis (RPGN)
• When DAH is present, RPGN co-exists in >90% of patients

• Eye: conjunctivitis, episcleritis, scleritis, proptosis from retro-orbital pseudotumor
• Nervous system: mononeuritis multiplex (up to one-third of patients), CNS vasculitis, pachymeningitis
• Cardiac: regional wall motion abnormalities, pericarditis, valvulitis
• Skin: leukocytoclastic vasculitis, palpable purpura

C. Histopathology

• Small-vessel vasculitis (capillaries, arterioles, venules)
• Geographic necrosis
• Hemorrhagic infarcts
• Mixed inflammatory cellular infiltrate
• Granulomatous component (distinguishes from MPA)

D. Severe vs Non-Severe GPA

• Severe GPA: threatens life (alveolar hemorrhage) OR vital organ with risk of irreversible damage (RPGN, scleritis, mononeuritis multiplex)
• Non-severe GPA: no immediate threat to life or irreversible organ damage

6. MICROSCOPIC POLYANGIITIS (MPA)

• Systemic small-vessel vasculitis without granulomatous inflammation of the respiratory tract
• Most common manifestation: pauci-immune necrotizing GN + DAH
• More frequent cause of pulmonary-renal syndrome than GPA
• ANCA-positive patients with pauci-immune DAH and GN are classified as MPA
• Can manifest as DAH limited to the lung or necrotizing GN limited to the kidney
• More than two-thirds of pulmonary-renal syndromes are ANCA-mediated (pauci-immune)

7. EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (EGPA)

• Characterized by: asthma + blood eosinophilia + granulomatous vasculitis
• Three phases: prodromal (allergic rhinitis, asthma), eosinophilic (tissue infiltration), vasculitic
• Leukotriene receptor antagonists may unmask EGPA by allowing steroid dose reduction (do NOT cause EGPA)
• Prognosis better than GPA and MPA
• Most deaths: secondary to cardiac involvement (cardiomyopathy, valvulitis, pericarditis)

8. ANCA SEROLOGY AND DIAGNOSIS

A. ANCA Patterns

• c-ANCA (cytoplasmic pattern) → PR3-ANCA → associated with GPA
• p-ANCA (perinuclear pattern) → MPO-ANCA → associated with MPA and EGPA

B. Current Diagnostic Approach

• High-quality antigen-specific PR3-ANCA and MPO-ANCA assays are recommended as the primary screening method
• If both negative with high suspicion: repeat assays or use IIF
• A positive ANCA contributes to but is not diagnostic by itself
• A negative ANCA does NOT rule out AAV - ANCA-negative pauci-immune vasculitis exists

C. ANCA and Disease Activity

• No clear relationship between ANCA titers and disease activity
• Increasing ANCA titers predicted relapse in only 40% of patients - not a reliable sole indicator
• In patients who are both PR3-ANCA and MPO-ANCA positive, drug-induced vasculitis should be considered

D. Drugs Causing ANCA-Associated Vasculitis

• Propylthiouracil, D-penicillamine, hydralazine, sulfasalazine, minocycline, allopurinol

9. DIFFUSE ALVEOLAR HEMORRHAGE (DAH)

• DAH results from pulmonary capillaritis - the hallmark histologic lesion
• In GPA: uncommon (<20%) but reflects diffuse microvascular injury
• In MPA: occurs in 10-50% and is a major cause of pulmonary-renal syndrome
• Classic triad: hemoptysis + diffuse bilateral alveolar infiltrates + falling hemoglobin
• Note: hemoptysis may be absent in up to one-third

10. TREATMENT

A. Remission Induction

• Rituximab (anti-CD20 monoclonal antibody) OR Cyclophosphamide (CYC) + high-dose glucocorticoids
• Rituximab is now preferred over CYC for remission induction (non-inferior, less toxic)
• In life-threatening DAH or severe renal disease: consider plasma exchange (PLEX)

• Methotrexate (MTX) or Mycophenolate mofetil (MMF) + glucocorticoids

B. Remission Maintenance

• After 3-6 months of induction, switch to less toxic agents:
  • Rituximab (preferred) - given every 6 months
  • Azathioprine (AZA)
  • Methotrexate (MTX)
• Treatment continued minimum 12-18 months (total duration)

C. Historical Context

• From early 1970s: oral CYC (2 mg/kg/day) + prednisone was standard for >4 decades
• Remissions achieved in 70-93% of patients; early mortality <15%

D. Relapse

• PR3-ANCA patients have higher relapse rates than MPO-ANCA patients
• Rising ANCA titers alone are an insufficient basis for pre-emptive treatment escalation

11. PROGNOSIS

• Untreated GPA: historically near-universal mortality within 1-2 years
• With modern therapy: remission in 70-93%
• EGPA has better prognosis than GPA/MPA; deaths mainly from cardiac involvement
• PR3-ANCA patients: higher relapse rate, faster renal function loss
• MPO-ANCA patients: lower relapse rate, better renal outcomes

SUMMARY TABLE